Three Ways to Die: How Ferroptosis, Cuproptosis and Pyroptosis Shape Cancer

Cancer cells are famously difficult to kill, and much of modern oncology has been built on the assumption that apoptosis—the tidy, silent self-destruction of cells—is the main route by which tumors can be eliminated. A sweeping new review in Molecular Cancer argues that this picture is no longer sufficient. Researchers led by Yixuan Liu, Jiachen Liu, and colleagues at Central South University and Washington University in St. Louis present what they call an “interconnected death” framework, in which three non-apoptotic forms of programmed cell death—ferroptosis, cuproptosis, and pyroptosis—do not act as isolated switches but as a coupled network that jointly governs tumor progression, metabolic adaptation, and the response to therapy. Their analysis, published as an open-access review, synthesizes hundreds of mechanistic studies into a single conceptual map of how these death pathways talk to one another and how tumors exploit that conversation to survive.

Ferroptosis, the most intensively studied of the three, is an iron-dependent form of cell death driven by the catastrophic oxidation of lipids in cellular membranes. It arises when the cell’s antioxidant defenses fail to neutralize lipid peroxides, particularly in membranes enriched with polyunsaturated fatty acids. The central guardian of this system is the enzyme glutathione peroxidase 4 (GPX4), which detoxifies lipid hydroperoxides using the cellular antioxidant glutathione. When cystine import through the transporter SLC7A11/xCT is blocked—by drugs such as erastin and its clinically improved analog imidazole ketone erastin—or when GPX4 is inhibited directly by compounds like RSL3, lipid peroxides accumulate until membranes rupture. Back-up systems exist: ferroptosis suppressor protein 1 (FSP1) regenerates coenzyme Q at the plasma membrane, and dihydroorotate dehydrogenase (DHODH) performs a similar protective role in mitochondria. Iron availability, ferritin storage and release, transferrin uptake, and the membrane remodeling enzyme ACSL4 all tune a cell’s sensitivity to this death mode.

Cuproptosis is the newest and most enigmatic member of the trio. Identified only in recent years, it depends on mitochondrial metabolism rather than lipid chemistry. Excess copper, transported into the cell by CTR1/SLC31A1 and exported by ATP7A and ATP7B, binds directly to the lipoylated components of the tricarboxylic acid cycle—most notably the enzyme DLAT, dihydrolipoamide S-acetyltransferase. This binding triggers toxic aggregation of lipoylated proteins, destabilizes iron-sulfur cluster proteins such as FDX1-dependent pathways, and causes a distinctive form of proteotoxic stress that kills the cell. Unlike ferroptosis, cuproptosis is tightly coupled to mitochondrial respiration: cells relying heavily on oxidative phosphorylation appear more vulnerable, which immediately suggests that the metabolic state of a tumor could determine whether copper-based strategies are feasible.

Pyroptosis, by contrast, is a death program built for alarm. It is executed by the gasdermin family of proteins—GSDMD, GSDME, GSDMC, and GSDMB among them—which, when cleaved by inflammatory caspases or even by executioner caspases downstream of apoptosis, form pores in the plasma membrane. The cell swells, bursts, and releases its contents, including potent damage-associated molecular patterns such as HMGB1 and mature interleukin-1β and interleukin-18 processed by the NLRP3 inflammasome. Pyroptosis is thus intrinsically inflammatory: it is the body’s way of announcing infection or danger to the immune system. In the tumor context, this makes pyroptosis a double-edged sword—capable of igniting antitumor immunity, but also of fueling chronic inflammation that can support tumor growth.

The central contribution of the review is its insistence that these three programs do not operate in isolation. The authors organize the crosstalk around five shared hubs: mitochondrial metabolism, glutathione and redox homeostasis, lipid peroxidation, autophagy, and immune-inflammatory signaling. Mitochondria sit at the center of the network. Reactive oxygen species generated by the respiratory chain feed lipid peroxidation and push cells toward ferroptosis, while the same metabolic activity determines copper’s ability to aggregate TCA-cycle proteins and trigger cuproptosis. Hypoxia-inducible factor 1α, activated in oxygen-poor tumor regions, reshapes metabolism in ways that alter sensitivity to all three programs simultaneously. A cell’s position along the metabolic spectrum—from glycolytic to oxidative—therefore acts as a master determinant of which death route is open.

Redox homeostasis provides a second connecting thread. The glutathione system, the NRF2 transcriptional program, and NADPH-generating pathways defend against ferroptosis, but they also buffer the oxidative stress that accompanies copper overload and inflammasome activation. When cancer cells upregulate SLC7A11 or NRF2 to resist ferroptosis, they may simultaneously blunt their capacity for pyroptosis-driven inflammatory signaling, changing how the immune system perceives the tumor. Conversely, autophagy—which the review treats as a dynamic regulator rather than a death pathway itself—can supply iron through the degradation of ferritin via NCOA4, sensitizing cells to ferroptosis, while also modulating inflammasome activity and mitochondrial quality. The same cellular machinery, deployed in different contexts, can push a cell toward different deaths.

What makes the framework clinically provocative is its emphasis on context: the biological outcome of a death event depends on the shared stress input, the identity of the dying cell, the spatial and temporal pattern of its demise, and the reactions of neighboring cells. Ferroptosis in a cancer cell within an immune-hot tumor can release signals that recruit dendritic cells and enhance T cell activity; the same ferroptosis in a tumor-associated macrophage or a myeloid-derived suppressor cell may instead suppress immunity. Pyroptosis of cancer cells can convert immunologically cold tumors into hot ones, synergizing with PD-1/PD-L1 checkpoint blockade, yet chronic gasdermin-driven inflammation in stromal cells can promote metastasis and epithelial-mesenchymal transition. Even cancer-associated fibroblasts and regulatory T cells participate, dying or resisting death in ways that reshape the tumor microenvironment’s balance of suppression and attack.

The review also connects this death network to tumor evolution itself. During tumor initiation and clonal selection, cells that acquire metabolic traits—elevated antioxidant capacity, altered iron handling, reduced lipoylation-dependent respiration—gain resistance to multiple death modalities at once. This pleiotropic resistance helps explain why tumors treated with a single death-inducing agent so often relapse. Cancer cells can additionally deploy regulatory plasticity: switching from one suppressive mechanism to another, such as moving from GPX4 dependence to FSP1 or DHODH-mediated protection, or exploiting cell-type-specific vulnerabilities in their surroundings to promote immune evasion and therapy resistance. The authors argue that only multimodal strategies—combining pathway-selective inducers, rational drug pairings, and targeted delivery systems such as nanoparticles engineered to deliver copper together with oxidative catalysts—can corner a tumor that has so many escape routes.

Translational challenges remain formidable. Ferroptosis inducers have entered early clinical testing, but biomarkers that reliably report ferroptosis activity in patients are still immature, and systemic toxicity—particularly to tissues rich in iron or poor in antioxidant reserves—demands careful dosing and delivery. Cuproptosis remains mechanistically young: whether copper ionophores kill cells purely through the lipoylated-protein aggregation pathway or through additional copper-dependent toxicities is still being resolved, and patient selection based on tumor metabolism is in its infancy. Pyroptosis-inducing strategies, including those embedded in emerging CAR T cell and nanoparticle platforms, must walk a narrow line between sufficient inflammation to recruit immunity and dangerous cytokine cascades. The authors also note gaps in our understanding of how these pathways intersect in specific organs, how sex and age modify them, and how best to measure crosstalk rather than individual pathways in clinical samples.

Nevertheless, the “interconnected death” concept offers oncology a new organizing principle. Instead of asking whether a drug induces ferroptosis or pyroptosis, the field may increasingly ask which combination of stress inputs—lipid peroxidation, copper overload, gasdermin activation, metabolic disruption—delivered to which cell types, at what sequence in the course of treatment, will tip an entire tumor ecosystem toward destruction while alerting the immune system rather than exhausting it. By mapping the shared wiring of three previously separate death programs, Liu, Liu, and their colleagues provide a conceptual foundation for precision approaches that treat programmed cell death not as a set of isolated switches, but as an integrated circuit—one that cancer has learned to rewire, and which medicine is now learning to rewire back.

Subject of Research: Crosstalk among the programmed cell death pathways ferroptosis, cuproptosis, and pyroptosis in cancer

Article Title: Interconnected death: crosstalk among ferroptosis, cuproptosis, and pyroptosis in cancer

Article References: Liu, Y., Liu, J., Zeng, D., Chen, L., Wei, C., Qiu, X., Fu, L., & Deng, Z. (2026). Interconnected death: crosstalk among ferroptosis, cuproptosis, and pyroptosis in cancer. Molecular Cancer. https://doi.org/10.1186/s12943-026-02799-z

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02799-z

Keywords: ferroptosis, cuproptosis, pyroptosis, programmed cell death, tumor microenvironment, metabolic crosstalk, lipid peroxidation, GPX4, gasdermins, antitumor immunity, therapy resistance, redox homeostasis